Replimune REPL
NASDAQ REPL
$12.94 -0.06 (-0.50%)
As of: Sep 30, 2026 · 10:01 AM EDT

Replimune (REPL) Long-Term Debt Repayments (2020 - 2026)

Updated

Replimune (REPL) posted Long-Term Debt Repayments of $203,000 for fiscal Q1 2027 (quarter ended Jun 30, 2026), up 22.3% from $166,000 a year earlier and up 2.5% from the prior quarter.

Analysis

Replimune (REPL) Long-Term Debt Repayments (2020 - 2026) Analysis & Trends

For the trailing twelve months through Jun 30, 2026, Long-Term Debt Repayments at Replimune was $773,000, up 22.5% year-over-year; for FY2026 (ended Mar 31, 2026), it was $736,000, up 22.9% from FY2025.

  • Annual Long-Term Debt Repayments has increased for four consecutive fiscal years, though with a five-year compound annual growth rate of -40.7% (FY2021 to FY2026).
  • In prior fiscal years, Replimune's Long-Term Debt Repayments was $599,000 in FY2025 (+25.8%), $476,000 in FY2024 (+30.4%), $365,000 in FY2023 (+38.3%) and $264,000 in FY2022 (-97.4%).
  • The fiscal Q1 2027 figure stands as the highest quarterly Long-Term Debt Repayments since fiscal Q3 2021.
  • On a year-over-year basis, Long-Term Debt Repayments has increased in each of the last 17 quarters, with growth averaging 23.7% over the last eight quarters.
  • The strongest year-over-year quarter for Long-Term Debt Repayments in the past five years was fiscal Q2 2022, with growth of 510.0%; the weakest was fiscal Q3 2022, with a decline of 99.3%.
  • According to Business Quant data, Long-Term Debt Repayments for the three prior fiscal quarters was $198,000 (Q4 2026), $195,000 (Q3 2026) and $177,000 (Q2 2026).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) LT Debt Repayment (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn 1.00 Mn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn 2.00 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn 5.00 Mn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn -
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn -2.45 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn -
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn 17.00 Mn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn -
10 Replimune 1.05 Bn 1.05 Bn - 203,000.00
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 203,000.00
Mar 31, 2026 198,000.00
Dec 31, 2025 195,000.00
Sep 30, 2025 177,000.00
Jun 30, 2025 166,000.00
Mar 31, 2025 163,000.00
Dec 31, 2024 159,000.00
Sep 30, 2024 143,000.00
Jun 30, 2024 134,000.00
Mar 31, 2024 131,000.00
Dec 31, 2023 128,000.00
Sep 30, 2023 113,000.00
Jun 30, 2023 104,000.00
Mar 31, 2023 103,000.00
Dec 31, 2022 99,000.00
Sep 30, 2022 86,000.00
Jun 30, 2022 77,000.00
Mar 31, 2022 76,000.00
Dec 31, 2021 74,000.00
Sep 30, 2021 61,000.00
API Access

Replimune Long-Term Debt Repayments API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=long-term-debt-repayments&ticker=REPL&period=max&api_key=YOUR_API_KEY